Tevogen Bio (NASDAQ:TVGN) Given a $4.20 Price Target by Fundamental Research Analysts

Tevogen Bio (NASDAQ:TVGN) received a $4.20 price target from stock analysts at Fundamental Research in a research report issued to clients and investors on Friday, BayStreet.CA reports. The brokerage presently has a “buy” rating on the stock. Fundamental Research’s price objective would suggest a potential upside of 483.33% from the stock’s previous close.

Tevogen Bio Trading Down 1.4 %

Shares of NASDAQ:TVGN traded down $0.01 during trading hours on Friday, hitting $0.72. The stock had a trading volume of 89,467 shares, compared to its average volume of 603,500. The firm has a fifty day moving average price of $0.93. Tevogen Bio has a 1-year low of $0.66 and a 1-year high of $21.09.

Institutional Trading of Tevogen Bio

An institutional investor recently bought a new position in Tevogen Bio stock. Portland Global Advisors LLC purchased a new stake in Tevogen Bio Holdings Inc. (NASDAQ:TVGN) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,782,209 shares of the company’s stock, valued at approximately $21,683,000. Tevogen Bio makes up about 3.0% of Portland Global Advisors LLC’s portfolio, making the stock its 9th biggest position. Portland Global Advisors LLC owned approximately 36.55% of Tevogen Bio as of its most recent filing with the Securities and Exchange Commission.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.